Intensified screening for SARS-CoV-2 in 18 emergency departments in the Paris metropolitan area, France (DEPIST-COVID): A cluster-randomized, two-period, crossover trial Authors: Judith Leblanc, Lisbeth Dusserre-Telmon, Anthony Chauvin, Tabassome Simon, Chiara E. Sabbatini, Karla Hemming, Vittoria Colizza, Laurence Bérard, Jérome Convert, Sonia Lazazga, Carole Jegou, Nabila Taibi, Sandrine Dautheville, Damien Zaghia, Camille Gerlier, Muriel Domergue, Florine Larrouturou, Florence Bonnet, Arnaud Fontanet, Sarah Salhi, Jérome LeGoff, Anne-Claude Crémieux, On behalf of the DEPIST-COVID group, FHU IMPEC (Improving Emergency Care) group, Richard Turner, Alexandra Schaefer, Alexandra Schaefer, Alexandra Schaefer Published: 2023 ABSTRACT BackgroundAsymptomatic and paucisymptomatic infections account for a substantial portion of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) transmissions. The value of intensified screening strategies, especially in emergency departments (EDs), in reaching asymptomatic and paucisymptomatic patients and helping to improve detection and reduce transmission has not been documented. The objective of this study was to evaluate in EDs whether an intensified SARS-CoV-2 screening strategy combining nurse-driven screening for asymptomatic/paucisymptomatic patients with routine practice (intervention) could contribute to higher detection of SARS-CoV-2 infections compared to routine practice alone, including screening for symptomatic or hospitalized patients (control).Methods and findingsWe conducted a cluster-randomized, two-period, crossover trial from February 2021 to May 2021 in 18 EDs in the Paris metropolitan area, France. All adults visiting the EDs were eligible. At the start of the first period, 18 EDs were randomized to the intervention or control strategy by balanced block randomization with stratification, with the alternative condition being applied in the second period. During the control period, routine screening for SARS-CoV-2 included screening for symptomatic or hospitalized patients. During the intervention period, in addition to routine screening practice, a questionnaire about risk exposure and symptoms and a SARS-CoV-2 screening test were offered by nurses to all remaining asymptomatic/paucisymptomatic patients. The primary outcome was the proportion of newly diagnosed SARS-CoV-2–positive patients among all adults visiting the 18 EDs. Primary analysis was by intention-to-treat. The primary outcome was analyzed using a generalized linear mixed model (Poisson distribution) with the center and center by period as random effects and the strategy (intervention versus control) and period (modeled as a weekly categorical variable) as fixed effects with additional adjustment for community incidence.During the intervention and control periods, 69,248 patients and 69,104 patients, respectively, were included for a total of 138,352 patients. Patients had a median age of 45.0 years [31.0, 63.0], and women represented 45.7% of the patients. During the intervention period, 6,332 asymptomatic/paucisymptomatic patients completed the questionnaire; 4,283 were screened for SARS-CoV-2 by nurses, leading to 224 new SARS-CoV-2 diagnoses. A total of 1,859 patients versus 2,084 patients were newly diagnosed during the intervention and control periods, respectively (adjusted analysis: 26.7/1,000 versus 26.2/1,000, adjusted relative risk: 1.02 (95% confidence interval (CI) [0.94, 1.11]; p = 0.634)). The main limitation of this study is that it was conducted in a rapidly evolving epidemiological context.ConclusionsThe results of this study showed that intensified screening for SARS-CoV-2 in EDs was unlikely to identify a higher proportion of newly diagnosed patients.Trial registrationTrial registration number: ClinicalTrials.gov NCT04756609. Introduction Countries have experienced several waves of the Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) pandemic, with considerable health and economic impacts [1]. Containing the pandemic was challenged by undetected asymptomatic or paucisymptomatic infections, which are estimated to account for nearly half of all transmissions [2–4]. In many countries, along with nonpharmaceutical control measures, widely available and free screening for SARS-CoV-2 has been offered in communities to reach infected asymptomatic/paucisymptomatic individuals who would otherwise not be tested. Mass screening experiments have been conducted at the city or country level [5–7]. In Slovakia, a population-wide screening program in 2020 led to a reduction in the prevalence of infection [6]. In 2020 to 2021, community-based asymptomatic screening in Liverpool was associated with a reduction in Coronavirus Disease 2019 (COVID-19)-related hospital admissions compared with a control population in England [7]. Difficulties in reaching the most deprived populations have been noted in these screening programs [5,8], as well as technical constraints due to the high volume of tests [6] and/or the poor sensitivity of some antigenic tests. Overall, research evaluating the impact of SARS-CoV-2 screening programs on improving detection, reducing transmission, and contributing to containing the pandemic is scarce. A recent systematic review also noted that these studies were modeling studies or retrospective observational analyses not conducted in a controlled environment [9]. A possible wide screening strategy for identifying asymptomatic/paucisymptomatic individuals is to systematically offer screening during medical consultations, particularly in emergency departments (EDs). French EDs receive a volume equivalent to one-third of the French population each year [10,11] and provide access to a large portion of the population, including low-income groups who may be less reached by the general screening system. Therefore, intensified SARS-CoV-2 screening in EDs could contribute to epidemic control and provide an opportunity to observe viral evolution. In addition to SARS-CoV-2 screening in EDs for symptomatic patients, screening at the time of hospital admission has been mandatory since mid-2020 in European countries to limit nosocomial transmission after studies showed that a high number of inpatients, up to 50% of new positive cases, were asymptomatic carriers [12,13]. Evaluations of screening practices in EDs for inpatients highlighted the value of the strategy during periods of high prevalence [13–17]. However, to our knowledge, no study has evaluated the benefit of extending screening to all patients who visit EDs in reaching asymptomatic and paucisymptomatic infectious individuals and helping improve detection. The lessons learned from the implementation and evaluation of such measures could be useful in preparing for future epidemics. The objectives of this trial were to offer an intensified screening strategy in 18 EDs in the Paris metropolitan area before the broad vaccine roll-out in May 2021 to evaluate whether this strategy could contribute to a higher detection proportion of SARS-CoV-2 infections during a period covering the third wave caused by the SARS-CoV-2 Alpha variant. Methods Ethics approval The protocol was approved by the Committee for Patient Protection Ile-de-France II (n°20.12.21.34036 MS1 RIPH 2 HPS) and by the French Data Protection Authorities. The study was also approved by the Scientific and Ethical Committee of Assistance Publique–Hopitaux de Paris (AP-HP) clinical data warehouse (IRB00011591) allowing to retrieve the ED flow data. AP-HP clinical data warehouse initiative ensures patients’ information and consent regarding the approved studies through a transparency portal in accordance with European Regulation on data protection and authorization (number 1980120) from the National Freedom and Informatics Commission. The trial was registered at ClinicalTrials.gov (NCT04756609). Study design and setting A cluster-randomized, two-period, crossover trial was conducted from February 17, 2021 to May 31, 2021, to evaluate the value of an intensified SARS-CoV-2 screening strategy combining nurse-driven screening for asymptomatic/paucisymptomatic patients with routine screening practice (intervention) compared to routine screening practice alone (control) in 18 EDs. Routine screening practice included screening symptomatic or hospitalized patients. The protocol of the ANRS|MIE DEPIST-COVID trial is available in Appendix A in S1 File (ANRS-MIE refers to the “Agence nationale de recherche sur le sida et les hépatites virales | Maladies Infectieuses Emergentes”). The Paris metropolitan region, divided into 8 geographical departments, includes more than 12 million people [10]. Annual visits to the 18 EDs located in 5 geographical departments represent 28% of the ED visits in the region (Appendix B in S1 File). All 18 invited EDs agreed to participate. Selection of participants Information about this study was provided to patients through posters in the EDs during each study period. An individual information note was given to patients who met the inclusion criteria (>18 years) on arrival to obtain their express informed consent to participate in this study and data collection during each study period, in accordance with French law (Appendix A in S1 File). During the intervention period, in addition to routine screening practice, all asymptomatic/paucisymptomatic patients were offered a questionnaire and a screening test. Randomization The unit of randomization was the ED. The strategy (control/intervention) applied during the first period was assigned using a balanced block randomization process with stratification based on ED flow and, for feasibility concerns, whether the ED had a SARS-CoV-2 screening device (block size of 2 to 6). The alternative strategy was applied during the second period after a minimum 1-day washout interval. The allocation schedule was computer generated in SAS by an independent statistician. The duration of each period was a minimum of 1 month with the possibility of a 15-day extension for the interested EDs, retaining similar durations for the same center in each period. The patients and teams could not be masked to allocation due to the nature of the intervention. Control condition During the control period, patients who were referred for suspected SARS-CoV-2 infection or who verbally reported symptoms of SARS-CoV-2 infection followed a specific patient pathway on admission that included physician-driven SARS-CoV-2 molecular screening. Patients who met the severity criteria (i.e., high acuity) [18] or who could be hospitalized were also screened. The practice was not modified in any way. For centers that had started with the intervention, the equipment provided was removed during the washout period, and EDs returned to their routine practice. Intervention Before the intervention period, nurses participated in a 1-h training session, including an educational lecture and a test demonstration. The centers that did not have the equipment were provided with the machines (Appendix C in S1 File). During the intervention period, in addition to routine screening for symptomatic patients or inpatients, a questionnaire was offered to the remaining asymptomatic/paucisymptomatic patients. The paper-based questionnaire on sociodemographic characteristics, SARS-CoV-2 symptoms and risk exposure was offered to patients who could provide consent (Appendix A in S1 File). The questionnaire was completed by the patient or with the help of the nurse. The questionnaire, further referred to as the DEPIST-COVID questionnaire, was not provided to patients with confirmed or highly suspected SARS-CoV-2 infection. The questionnaire was developed by the research team based on other questionnaires [19,20]. During triage assessment, a rapid screening test by nasopharyngeal swabs was offered by nurses on a 24-h basis to all patients who completed the questionnaire. The type of test was chosen according to the symptoms recorded on the questionnaire (asymptomatic versus paucisymptomatic). Paucisymptomatic patients were defined as those with mild symptoms reported on the questionnaire that were not the reason for consultation or not spontaneously reported by the patient at registration. For paucisymptomatic patients, samples were tested with the multiplex polymerase chain reaction (PCR) assay QIAstat-Dx respiratory SARS-CoV-2 panel, further referred to as the rapid multiplex respiratory virus test, which detects 21 viruses and bacteria and provides results within 70 min [21]. For asymptomatic patients, samples were tested with the Abbott ID NOW COVID-19 assay, an isothermal nucleic acid amplification assay based on a nicking and extension amplification reaction (NEAR) technique. The assay, further referred to as the rapid molecular SARS-CoV-2 test, targets the RNA-dependent RNA polymerase (RdRp) gene segment and provides results within 5 to 13 min [22]. Nasopharyngeal swabs were tested directly, without dilution in viral transport medium. Patients with a positive SARS-CoV-2 test were cared for according to local procedures. During the intervention period, a clinical research assistant was on site 5 days a week to facilitate staff adherence and monitor data collection. Measurements Data from the DEPIST-COVID questionnaires were entered into a database (CleanWEB Telemedicine Technologies SAS, Boulogne-Billancourt, France). ED flow data, including patient and center characteristics, and SARS-CoV-2 routine screening data were extracted from electronic ED databases. Community screening data routinely collected for all individuals screened in the Paris metropolitan region [23], including symptomatic status, were provided by Santé Publique France. Outcomes The primary outcome was the proportion of newly diagnosed SARS-CoV-2–positive patients among all adults visiting the 18 EDs during the study period. Patients who tested positive and whose SARS-CoV-2–positive status was not already known were considered positive. Unscreened patients or those whose test result was negative, indeterminate, or positive with a known status <3 months prior were classified as nonpositive. The secondary outcomes were as follows: (a) implementation of ED screening for asymptomatic/paucisymptomatic patients, including the proportion of patients who completed the questionnaire; the proportion of screening tests that were offered, accepted, and performed; and patient characteristics reported in the DEPIST-COVID questionnaire; (b) the proportion of new SARS-CoV-2 infections diagnosed through ED screening for asymptomatic/paucisymptomatic patients and patient characteristics, and the proportion of patients who tested positive for other respiratory viruses; (c) the proportions of new SARS-CoV-2 infections diagnosed through ED screening for asymptomatic/paucisymptomatic patients versus the proportions of positive tests through community screening for asymptomatic adults in the geographical departments of the Paris metropolitan region during the same period, overall and per ED; the proportion of new SARS-CoV-2 infections diagnosed through ED screening for all patients versus the proportion of positive tests through community screening for all adults in the geographical departments of the Paris metropolitan region during the same period; and (d) the proportions of new SARS-CoV-2 infections diagnosed through ED screening versus the incidence rate in the Paris metropolitan region estimated from an age-stratified disease model for SARS-CoV-2 transmission. Sample size calculation The estimate of the sample size was based on the comparison of 2 proportions under individual randomization using Fisher’s exact test, with 0.1% of newly diagnosed SARS-CoV-2–positive patients among the included patients (control) and 0.2% (intervention), with a 2-sided significance, α = 5%, and β = 10%. Taking the intracluster (rho = 0.00014) and between-cluster (rho12 = 0.00009) correlations previously estimated [24] into account, 104 000 patients were needed. The proportion of the control group was based on the incidence rate of 0.12% in the Paris metropolitan region on 26/11/2020. It was estimated that the proportion of 0.10% was close to the baseline proportion of new diagnoses among ED patients with routine screening. Simulations were performed using different incidence rates; the worst-case scenario involving the largest number of patients to be included was selected. The calculation was performed by an independent biostatistician with SAS software (version 9.4; SAS Institute, Cary, North Carolina, United States of America). Statistical analysis Primary analysis was performed according to the intention-to-treat principle. The primary outcome was analyzed using a generalized linear mixed model (Poisson distribution) with the center as a random intercept, the center-by-period interaction as a random effect and the strategy (intervention versus control), period, and community incidence rate-by-period interaction as covariates. The logarithm of the number of patients was included as an offset term. The parameters of the model were estimated using a full maximum-likelihood method with the Laplace method (SAS PROC GLIMMIX). The P values reported for covariates were based on t tests using the Kenward–Roger approximation for the denominator degrees of freedom. The period was modeled as a weekly categorical variable (1–15). The community incidence rate in the population of the local geographical department in the corresponding period and center was calculated among individuals aged 20+ years (data available only for this age category) [10,23]. Intercluster and intracluster correlation coefficients were calculated. In sensitivity analyses, the period was modeled as a binary variable; variables used for randomization (screening equipment, flow) and intervention-by-week since roll-out interaction were included as covariates. Another sensitivity analysis was performed at the center level. For patients with multiple tests in 24 h, a single result was considered; it was considered positive in the case of a positive result. ED visits and test results for the same patient separated by more than 24 h were considered separately. The implementation of ED screening for asymptomatic/paucisymptomatic patients was described. Factors associated with performing ED screening for asymptomatic/paucisymptomatic patients were analyzed among patients who were offered screening using a generalized linear mixed model (binomial distribution) with the center as a random intercept and the patient characteristics as fixed effects. Patients who accepted screening but whose screening test was not performed for feasibility concerns were not included in the analysis. Missing data for covariates ranged from 0.2% to 15.6%. The proportions of new SARS-CoV-2 infections and other respiratory virus infections diagnosed through ED screening for asymptomatic/paucisymptomatic patients were described, as well as patient characteristics. The factors associated with new SARS-CoV-2 diagnoses through this screening were analyzed using a generalized linear mixed model (binomial distribution) with the center as a random intercept and the patient characteristics as fixed effects. Missing data for covariates ranged from 0.6% to 12.8%. In both models described above, the unit of analysis was the patient. Parameters were estimated with the Laplace method, and the fixed effects were estimated using the containment method. The variables that were found to be significant at P < 0.05 in bivariate analyses based on t tests were included in the models. Observations with missing data were excluded. The proportions of new SARS-CoV-2 infections diagnosed through ED screening for asymptomatic/paucisymptomatic patients overall and per ED, and the same proportion through ED screening for all patients were compared to the proportions of positive tests through community screening for adults screened in the geographical departments of the Paris metropolitan region using the Miettinen–Nurminen (MN) method [25–27] for risk difference and 95% confidence interval (CI) estimations. Pearson X2 test was used to test for differences in these secondary outcomes. Analysis for secondary outcomes used descriptive statistics, with numbers and proportions (qualitative data), and means, standard deviations or medians and the first quartile and third quartile (quantitative data). Differences and 95% CIs were estimated using the MN method (qualitative data) and the Brookmeyer–Crowley test (quantitative data). The analysis plan for estimating the incidence rate in the Paris metropolitan region is detailed below. The proportion of new diagnoses was considered among ED-tested patients. The proportion was calculated for patients screened through ED screening for asymptomatic/paucisymptomatic patients and for all patients screened. The results were compared to the predictions of an age-stratified disease model for transmission in the region, previously validated with serological data and used in France in 2020 to 2021 [28,29]. The model integrated data on demographics, age profile, social contacts, mobility, and the adoption of preventive measures over time. It included data on the roll-out of the vaccination campaign and estimates of vaccine effectiveness and accounted for the cocirculation of the historical strain and the Alpha variant, which became dominant during the study period. The age classes were [0–11), [11–19), [19–65), and 65+ years. Transmission dynamics followed a compartmental scheme specific for COVID-19, where individuals were divided into susceptible/exposed/infectious/hospitalized/recovered stages. The infectious stage included a prodromic phase followed by a phase where individuals may continue to either be asymptomatic (probability: 40%) [4] or develop symptoms with degrees of severity (paucisymptomatic, mild/severe symptoms). Fitted to daily regional hospital admissions, the model allowed to estimate the total number of cases and the detection rate of virological monitoring in the region. The analysis was performed using SAS software (version 9.4; SAS Institute, Cary, North Carolina, USA) and R 4.1.3 (2022-03-10). The code of the transmission model developed in Python 3 is available [28–30]. This study is reported as per the cluster randomized trials extension of the Consolidated Standards of Reporting Trials (CONSORT) guidelines (Appendix L in S1 File) [31]. Results Among the 73,340 patients who presented to the EDs during the intervention period and the 72,701 patients during the control period, 69,248 and 69,104 adults were included during the 2 periods, respectively, for a total of 138,352 patients (Fig 1). They had a median age of 45.0 years [31.0, 63.0], and women represented 45.7% of the patients. Patient characteristics are shown in Table 1. Participation of emergency departments and patient inclusion in the DEPIST-COVID trial. Data are presented as numbers or medians [first quartile; third quartile]. ED, emergency department. 10.1371/journal.pmed.1004317.t001Table 1Characteristics of the study participants.CharacteristicTotal population N = 138,352Control period n = 69,104Intervention period n = 69,248 N n (%) or median [Q1, Q3] N n (%) or median [Q1, Q3] N n (%) or median [Q1, Q3] Age (year) 132,865145.0 [31.0, 63.0]66,23745.0 [31.0, 64.0]66,62845.0 [30.0, 63.0] Sex 127,868266,24061,628Female58,474 (45.7)30,277 (45.7)28,197 (45.8) Center 138,35269,10469,248112,601 (9.1)6,420 (9.3)6,181 (8.9)27,448 (5.4)3,815 (5.5)3,633 (5.2)36,826 (4.9)3,388 (4.9)3,438 (5.0)47,304 (5.3)3,692 (5.3)3,612 (5.2)59,721 (7.0)5,183 (7.5)4,538 (6.6)67,180 (5.2)3,640 (5.3)3,540 (5.1)711,812 (8.5)5,972 (8.6)5,840 (8.4)810,763 (7.8)5,434 (7.9)5,329 (7.7)99,661 (7.0)4,696 (6.8)4,965 (7.2)105,014 (3.6)2,498 (3.6)2,516 (3.6)114,213 (3.0)1,989 (2.9)2,224 (3.2)124,654 (3.4)2,418 (3.5)2,236 (3.2)138,444 (6.1)4,205 (6.1)4,239 (6.1)146,422 (4.6)3,139 (4.5)3,283 (4.7)154,625 (3.3)2,378 (3.4)2,247 (3.2)166,109 (4.4)2,865 (4.1)3,244 (4.7)179,316 (6.7)4,635 (6.7)4,681 (6.8)186,239 (4.5)2,737 (4.0)3,502 (5.1)1 Missing data: n = 5,487 (4.0%). Age data were partially extracted at 2 centers.2 Missing data: n = 10,484 (7.6%). Sex data were partially extracted at 2 centers and were missing for 1 period at 1 center.Q1, first quartile; Q3, third quartile. Characteristics of the study participants. 1 Missing data: n = 5,487 (4.0%). Age data were partially extracted at 2 centers. 2 Missing data: n = 10,484 (7.6%). Sex data were partially extracted at 2 centers and were missing for 1 period at 1 center. Q1, first quartile; Q3, third quartile. Intervention delivery During the intervention period, the questionnaire was offered to 6,428 (13.6%) of 47,234 eligible patients (Fig 2). Among them, 6,332 (98.5%) patients agreed to complete the questionnaire. SARS-CoV-2 screening was offered to 5,984 (94.5%) asymptomatic/paucisymptomatic patients. Of the 1,793 patients offered screening for whom ED discharge data were available, 1,769 (98.7%) were not hospitalized (outpatients) (Appendixes D and K in S1 File). Flow diagram. For the primary outcome, all patients were analyzed according to the intention-to-treat principle. *Twenty-four patients with initial indeterminate SARS-CoV-2 results were retested: 2 had positive results, 16 had negative results, and 6 had indeterminate results. **The “rapid multiplex test” refers to the multiplex PCR assay QIAstat-Dx respiratory SARS-CoV-2 panel. The “rapid molecular test” refers to the Abbott ID NOW COVID-19 assay, an isothermal nucleic acid amplification assay based on a NEAR technique. CI, confidence interval; ED, emergency department; NEAR, nicking and extension amplification reaction; PCR, polymerase chain reaction; SARS-CoV-2, Severe Acute Respiratory Syndrome Coronavirus 2. Overall, 4,283 asymptomatic/paucisymptomatic patients were screened, including 3,682 (86.0%) patients who underwent a rapid molecular SARS-CoV-2 test, resulting in 224 (5.2%) new SARS-CoV-2 diagnoses. Among the asymptomatic/paucisymptomatic patients screened, 80.9% did not report symptoms and 41.6% reported not having been tested previously. Of the 224 newly diagnosed patients, 38.4% did not report symptoms (Appendix E in S1 File). Among the 601 patients who underwent a rapid multiplex respiratory virus test, 116 (19.3%) were newly diagnosed with SARS-CoV-2, including 5 diagnosed with other respiratory viruses, and 72 (12.0%) who tested negative for SARS-CoV-2 were positive for another virus. During the intervention period, 17,512 patients were screened in routine practice, resulting in 1,635 (9.3%) new SARS-CoV-2 diagnoses. In total, during this period, 1,859 patients were newly diagnosed among 69,248 patients (26.8/1,000 patients (95% CI [25.7, 28.1]) (Table 2). 10.1371/journal.pmed.1004317.t002Table 2Primary outcome data.New SARS-CoV-2 diagnosesTotal population N = 138,352Control period n = 69,104Intervention period n = 69,248Risk difference [95% CI] N n (%) N n (%) N n (%)138,35269,10469,248Yes3,943 (2.8)2,084 (3.0)1,859 (2.7)−0.33 [−0.51, −0.16]No134,409 (97.2)67,020 (97.0)67,389 (97.3)0.33 [0.16, 0.51]CI, confidence interval; SARS-CoV-2, Severe Acute Respiratory Syndrome Coronavirus 2. Primary outcome data. CI, confidence interval; SARS-CoV-2, Severe Acute Respiratory Syndrome Coronavirus 2. Control period During the control period, following 18,572 tests, 2,084 patients (11.2%) were newly diagnosed among 69,104 patients (30.2/1,000 (95% CI [28.9, 31.5]) (Fig 3, Appendixes F–H in S1 File). Study periods by emergency department and weekly incidence rate. Sources: Incidence: https://geodes.santepubliquefrance.fr/?view=map1&indics=sp_pe_std_quot.tx_std&serie=2022-01-31&lang=fr. Population: https://www.insee.fr/fr/statistiques/1893198. y.o., years old. Primary outcome After adjustment, the proportion of new diagnoses was 26.7 per 1,000 patients (95% CI [19.1, 37.3]) during the intervention period versus 26.2 per 1,000 patients (95% CI [18.8, 36.3]) during the control period (adjusted relative risk: 1.02 (95% CI [0.94, 1.11]; p = 0.634)). In sensitivity analyses, the findings were similar. The intracluster and intercluster correlation coefficients are reported in Appendix I in S1 File. Secondary outcomes The factors associated with performing screening for asymptomatic/paucisymptomatic patients were male sex (54.6% of patients screened versus 51.4% of patients who declined screening, OR: 1.21 (95% CI [1.05, 1.40])), mild symptoms (19.1% versus 6.4%, OR: 2.8 (95% CI [2.1, 3.7])), not being screened previously (41.6% versus 31.7%, OR: 1.4 (95% CI [1.2, 1.6])), and self-assessment of a high risk of infection (17.8% versus 14.2%, OR: 1.3 (95% CI [1.1, 1.6])) (Appendix D in S1 File). The factors associated with new diagnoses through screening for asymptomatic/paucisymptomatic patients were older age (OR: 1.02 (95% CI [1.01, 1.03]) per additional year), not being from France (54.4% of patients with new diagnoses versus 40% of patients who tested negative, OR: 1.7 (95% CI [1.2, 2.5])), particularly being from sub-Saharan Africa, having mild symptoms (61.6% versus 16.5%, OR: 7.3 (95% CI [5.1, 10.4])), being a case contact (29.7% versus 22.0%, OR: 1.8 (95% CI [1.2, 2.6])), and not being screened previously (57.7% versus 41.4%, OR: 2.1 (95% CI [1.5, 3.0])) (Appendix E in S1 File). At the regional level, the proportion of new diagnoses through ED screening for asymptomatic/paucisymptomatic patients was higher than the proportion of positive tests through community screening for asymptomatic adults in the departments of the Paris metropolitan region (224/4,283 (5.2%) and 156,298/3,400,584 (4.6%), respectively, risk difference: 0.6% (95% CI [0.01%, 1.3%]; p = 0.048)) (Appendix J in S1 File). The proportion of new diagnoses through ED screening for all patients was higher than the proportion of positive tests through community screening for adults in the departments of the Paris metropolitan region (3,943/40,367 (9.8%) and 361,089/4,680,491 (7.7%), respectively, risk difference: 2.1% (95% CI [1.8%, 2.3%]; p < 0.001)) (Appendix J in S1 File). The estimates from ED screening were compatible with the predictions of the mathematical model, yielding a regional incidence rate of asymptomatic/paucisymptomatic infections in adults of 4.1% (95% probability ranges [2.5%, 5.7%]) and a regional incidence rate in adults (symptomatic and asymptomatic) of 9.7% (95% probability ranges [6.1%, 13.8%]). Discussion During this large-scale study in EDs, we found that an intensified screening strategy for SARS-CoV-2 was unlikely to identify a substantial proportion of new diagnoses. Compared to the asymptomatic population screened in the region, the asymptomatic/paucisymptomatic ED population screened by nurses appears to have been more affected. Comparison with a mathematical model indicated that the ED data allowed for the estimation of regional incidences for asymptomatic/paucisymptomatic SARS-CoV-2 infections. In this study, screening for asymptomatic/paucisymptomatic patients led to the detection of SARS-CoV-2 in more than 200 patients. Almost all these patients were outpatients who would not otherwise have been screened during their visit. Despite a trend in the primary outcome analysis toward an increased detection of infections with the intervention, the 95% CI provided no support for values of importance, ranging from an 11% increase, which is of clinical interest, to a 6% decrease. Several reasons may explain these findings. First, 21% of the patients who visited the EDs were admitted and screened. When combined with the screening of symptomatic patients, more than 25% of patients were routinely screened. This high proportion of detection, facilitated by using fast molecular assays as point-of-care tests in half of the centers, is unprecedented and could have lowered the impact of the intervention. Second, the findings could be related to a highly fluctuating evolution of the COVID-19 epidemic during the study [7]. During the control period, for a similar flow, more tests appeared to be ordered for symptomatic patients or inpatients than during the intervention period (3,445 versus 2,903), with a positivity proportion that appeared to be higher (18.5% versus 16.6%). The changing epidemiological context alongside the lockdown period (April 03, 2021 to May 03, 2021) was probably imperfectly captured in the analysis, which confirmed a weekly period effect and an interaction with the incidence rate. The lockdown must have led to changes with probably reduced outpatient numbers (Appendix K in S1 File). The reduction in ED visits during the wave may have limited the role of EDs as an observatory of the epidemic. Third, out-of-hospital screening was generalized during the study period, possibly reducing the impact of the intervention. In 2021, 35 million tests were recorded in the Paris metropolitan area [23]. In 2023, as the pandemic state of emergency ends in most countries, community screening also abruptly decreases, which could renew the interest for ED observatories of the epidemics, as is the case in France for seasonal influenza. In this study, almost half of the asymptomatic/paucisymptomatic patients screened had not been previously tested for SARS-CoV-2, suggesting limited access to health care. The proportion of new diagnoses in this asymptomatic/paucisymptomatic population in EDs seemed to be higher than that in the asymptomatic population screened during the same period in the region. Positivity appeared higher in EDs in individuals born in countries other than France, corroborating studies reporting higher infection rates in minority groups [32]. These results indicate that EDs may provide access to a large population, including more deprived patients who may be less reached by the general screening system. This is one of the main strengths of this study. Community-based SARS-CoV-2 screening programs struggled to reach a wide range of populations and observed lower participation in most disadvantaged neighborhoods [8]. When epidemic growth is substantial, high levels of repeat screening should be maintained [33,34]. The strategy in EDs can allow repeat screening and specifically include high-risk groups. The findings in community screening and EDs reiterate the importance of examining strategies that overcome the effects of social and health inequalities and may inform the development of future interventions in other epidemics. Data from the implementation of the intensified SARS-CoV-2 screening strategy in EDs are difficult to compare. Most studies evaluating the effectiveness of SARS-CoV-2 screening in adult EDs either focus on screening symptomatic patients for diagnostic purposes or screening admitted patients to reduce nosocomial transmission, are modeling studies, or report on the accuracy of screening tests. Evaluation of community-based SARS-CoV-2 screening programs for asymptomatic individuals have involved few controlled comparisons of key health outcomes, such as the detection of positive cases, timely isolation of infectious individuals and their close contacts, transmissions, hospital admissions, or deaths. Furthermore, the evaluations conducted have often failed to distinguish between the impact of mass screening and a combination of other control measures introduced simultaneously. Large-scale community screening evaluated in 3 countries at rapidly growing phases of the epidemic appeared to have the potential to reduce prevalence, transmission, or subsequent hospitalizations, at least in the short term [6,7,34]. However, given the heterogeneity of the study designs, objectives, outcomes, or the absence of a comparison group, the findings cannot be directly compared with those obtained in EDs. In a study conducted in Switzerland in 2021 with repeat screening of approximately 27,000 individuals over 8 weeks, the authors favorably concluded that the screening program led to a reduction in the incidence rate of up to 50%, with approximately 200 positive tests observed, which is a raw number similar to that obtained with ED screening for asymptomatic/paucisymptomatic individuals [34]. Comparative evaluation of screening activities is crucial for identifying effective and equitable responses [7]. The results of the present study raise the issue of the study design choice in a changing epidemiological landscape. The alternative of a cluster randomization and crossover could have been a before-and-after design, but this would have resulted in difficult-to-control biases and a lower level of evidence; therefore, the chosen design was appropriate. There is concern that adding screening will have unintended consequences for ED workload. Contrasting results are reported on the impact of inpatient screening on ED length of stay [15,22]. Screening yield can also be limited by staff shortages, costs, or testing capacities, encouraging the adaptation of screening practices for asymptomatic inpatients and, similarly, for outpatients to individual-level risk assessment and regional incidence [13,16]. In terms of limitations, in addition to the factors described, including the high fluctuation during the epidemic which may have reduced the impact of the intervention, during this study, 14% of eligible ED patients completed the questionnaire, which was the first stage of the nurse-driven screening strategy for asymptomatic/paucisymptomatic individuals, 67% of whom were screened. This is inherent to screening strategies in EDs, in which the proportion of patients involved in the screening process rarely exceeds 20% [24,35]. However, considering the high volume of patients visiting EDs, the number of patients reached far exceeds that of other facilities in the same period. A rapid isothermal amplification assay was used for biosafety reasons and rapid turnaround time [22]. Although the performances of such assays might be questionable compared to PCR techniques, several studies evaluating the same test we used reported high specificity (>97.5%) and high sensitivity (>98.5%) provided that tests were performed with dry swabs after nasopharyngeal sampling [36–39]. The test provided qualitative results, and therefore, residual and presymptomatic infections could not be distinguished. The aim was also to choose a test that would be easy and safe for nurses with no prior experience or qualifications in laboratory testing. The test had to provide quick results, similar to lateral flow assays, possess a higher sensitivity for identifying asymptomatic individuals and offer result traceability. Finally, rapid isothermal assays offer testing options that may be more affordable than single automated real-time PCR assays, particularly in terms of cost of the system. For reasons of feasibility, our study could not include an evaluation of the costs in the 2 groups compared or an examination of the choice of tests. This is a major area since decisions about the adoption of control measures must reflect both effectiveness and costs [9]. Given the considerable asymptomatic transmission of SARS-CoV-2 infection, screening is a key nonpharmaceutical measure for identifying infectious individuals, limiting transmission, and containing the epidemic. During a rapidly evolving epidemic phase, we observed that the intensified screening strategy in EDs was unlikely to increase detection. However, comparing ED screening data with a mathematical model was encouraging, as it allowed estimation of regional incidences for both asymptomatic/paucisymptomatic SARS-CoV-2 infections and total cases. This approach can potentially be used to estimate the size of the epidemic in the population and the underdetection of cases in community surveillance [28,40,41]. The findings underline the need to further explore, using robust evaluation methods, ED strategies for the detection of SARS-CoV-2, or asymptomatically transmitted respiratory viruses to better define the observatory role of EDs in emerging epidemics. In conclusion, the results of this study showed that intensified ED screening was unlikely to bring a substantial benefit to the detection of SARS-CoV-2 infections. This strategy could facilitate access to a population that appears to be more affected than the population of the region and could help to estimate the incidence of asymptomatic/paucisymptomatic infections. Supporting information Appendix A. Study protocol including the initial statistical analysis plan (SAP) as submitted to French data authorities, the final SAP, a summary of the changes in the SAP, and the DEPIST-COVID questionnaire. Appendix B. Figure Geographical location of the 18 emergency departments involved in the DEPIST-COVID trial (Paris metropolitan area). Fig B1. Geographical location of the 18 emergency departments involved in the DEPIST-COVID trial (Paris metropolitan area). References: R Core Team (2022). R: A language and environment for statistical computing. R Foundation for Statistical Computing, Vienna, Austria. URL https://www.R-project.org/. Hijmans, R.J. (2022). raster: Geographic Data Analysis and Modeling. R package version 4.1.3. https://CRAN.R-project.org/package=raster. Appendix C. Table Emergency department characteristics and study period duration. Table C1. Emergency department characteristics and study period duration. Data are presented as numbers or No 0/Yes 1. ED: Emergency department. aAnnual patient admissions included pediatric admissions. bDuration of the intervention, control, and wash-out periods (days), median [first quartile, third quartile]: 34.5 [30.0, 36.0]; 34.5 [30.0, 36.0]; 1.5 [1.0, 2.0]. Appendix D. Table Characteristics of patients who underwent and declined SARS-CoV-2 screening for asymptomatic/paucisymptomatic patients during the intervention period. Table D1. Characteristics of patients who underwent and declined SARS-CoV-2 screening for asymptomatic/paucisymptomatic patients during the intervention period. * Patients who accepted the rapid test but did not have a test performed were not included in this table. In univariate analysis, factors associated with performing screening for asymptomatic/paucisymptomatic patients were the following: older age, male sex, having mild symptoms, not being from France, being unemployed, being followed up for a chronic disease, not being screened previously, and self-assessment of a high risk of infection. ** Chronic diseases: diabetes, arterial hypertension, angina pectoris, chronic bronchitis, asthma or chronic respiratory disease. *** For this variable of the DEPIST-COVID questionnaire, data were collected in 8 centers, and it was not possible to collect them later in the remaining 10 centers. Findings are presented for 8 centers (n = 2,226 patients, missing data: 19.5% in the 8 centers). Q1: first quartile; Q3: third quartile; CI: confidence interval. Appendix E. Table Characteristics of patients tested through SARS-CoV-2 screening for asymptomatic/paucisymptomatic patients. Table E1. Characteristics of patients tested through SARS-CoV-2 screening for asymptomatic/paucisymptomatic patients. * Patients with indeterminate results or a known positive SARS-CoV-2 status were not included in this table. In univariate analysis, factors associated with new infections diagnosed through nurse-driven screening for asymptomatic/paucisymptomatic patients were mainly older age, having mild symptoms, not being from France, particularly being from sub-Saharan Africa, being unemployed, not having medical coverage, living in a community, being a case contact and not being previously screened. ** Among patients who underwent a rapid molecular SARS-CoV-2 test, 258 (7.4%) reported having symptoms. Among patients who underwent a rapid multiplex respiratory virus test, 508 (90.1%) reported having symptoms. *** Chronic diseases: diabetes, arterial hypertension, angina pectoris, chronic bronchitis, asthma, or chronic respiratory disease. **** For this variable of the DEPIST-COVID questionnaire, data were collected in 8 centers, and it was not possible to collect them later in the remaining 10 centers. Findings are presented for 8 centers (n = 1,510 patients, missing data: 12.1% in the 8 centers). ***** Rhinovirus/Enterovirus: n = 29 (37.7%), Coronavirus OC43: n = 12 (15.6%), Coronavirus NL63: n = 10 (13.0%), Human Metapneumovirus A+B: n = 10 (13.0%), Respiratory Syncytial Virus A+B: n = 6 (7.8%), Parainfluenza virus 3: n = 3 (3.9%), Bocavirus: n = 2 (2.6%), Parainfluenza virus 4: n = 2 (2.6%), Bocavirus | Coronavirus HKU1: n = 1 (1.3%), Coronavirus 229E: n = 1 (1.3%), Influenza A: n = 1 (1.3%). Among SARS-CoV-2+ patients: Rhinovirus/Enterovirus: n = 2, Bocavirus: n = 1, Parainfluenza virus 4: n = 1, Respiratory Syncytial Virus A+B: n = 1. Q1: first quartile; Q3: third quartile; CI: confidence interval. Appendix F. Figure Newly diagnosed SARS-CoV-2-positive patients per emergency department and strategy. Fig F1. Newly diagnosed SARS-CoV-2–positive patients per emergency department and strategy. Appendix G. Figure SARS-CoV-2 incidence rate in the Paris metropolitan area and per geographical department (75, 77, 92, 93, 95) of the emergency departments involved in the study. Fig G1. SARS-CoV-2 incidence rate in the Paris metropolitan area and per geographical department (75, 77, 92, 93, 95) of the emergency departments involved in the study. y.o.: years old. Appendix H. Table Characteristics of patients newly diagnosed with SARS-CoV-2 infection. Table H1. Characteristics of patients newly diagnosed with SARS-CoV-2 infection. Q1: first quartile; Q3: third quartile; CI: confidence interval. Appendix I. Primary outcome modelling, sensitivity analyses, and intercluster and intracluster correlation coefficients. Table I1. Coefficient estimates from the generalized linear mixed model with a Poisson distribution including the center as a random intercept, the center-by-weekly period interaction as a random effect and the strategy, weekly period and incidence rate-by-weekly period interaction as fixed effects (SAS PROC Glimmix). Table I2. Significant random effects. Table I3. Analysis considering a binarized period (0/1). Table I4. Analysis including variables used for randomization (screening equipment in emergency departments and flow in emergency departments). Table I5. Analysis including strategy * week_since_roll_out interaction. Table I6. Analysis at the center level. Appendix J. Comparison of the proportions of new SARS-CoV-2 diagnoses through screening in emergency departments and of positive tests through community screening for individuals aged 18+ of the geographical departments of the Paris metropolitan area screened during the same period. Table J1. New SARS-CoV-2 infections diagnosed through screening in emergency departments for asymptomatic/paucisymptomatic patients and positive tests through community screening for asymptomatic adults in the geographical departments of the Paris metropolitan area during the same period.* Source: Community screening data were provided by Santé Publique France on May 20, 2022. Table J2. New SARS-CoV-2 infections diagnosed through screening in emergency departments (EDs) for asymptomatic/paucisymptomatic patients per ED and positive tests through community screening for asymptomatic adults tested in the corresponding geographical department.* Source: Community screening data were provided by Santé Publique France on May 20, 2022. Table J3. New SARS-CoV-2 diagnoses through screening in emergency departments and positive tests through community screening for adults in the geographical departments of the Paris metropolitan area during the same period.* Source: Community screening data were provided by Santé Publique France on May 20, 2022. Appendix K. Figures Visits in the 18 emergency departments during the study period in 2021 and during the same period in 2019. Fig K1. Visits to the 18 emergency departments during the same period of the year in 2019 and 2021. Source: Observatoire Régional des Soins Non Programmés (ORNSP). Activité des services d’urgences en Ile-de-France 2021 [Available from: https://orsnp-idf.fr/wp-content/uploads/2022/06/20220606_rapport_annuel_urgences_2021_VF.pdf. Published: June 2022. Accessed date: 07/06/2023]. Fig K2. Proportion of emergency department visits without hospital admission per week in the 18 emergency departments during the same period in 2019 and in 2021. Source: Observatoire Régional des Soins Non Programmés (ORNSP). Activité des services d’urgences en Ile-de-France 2021 [Available from: https://orsnp-idf.fr/wp-content/uploads/2022/06/20220606_rapport_annuel_urgences_2021_VF.pdf. Published: June 2022. Accessed date: 07/06/2023]. Appendix L. Cluster randomised trials extension of the Consolidated Standards of Reporting Trials (CONSORT) checklist. Appendix M. Study group. (PDF) Click here for additional data file. 6 Jun 2023 Dear Dr Leblanc, Thank you for submitting your manuscript entitled "INTENSIFIED SCREENING FOR SARS-CoV-2 IN 18 EMERGENCY DEPARTMENTS THE CLUSTER-RANDOMIZED, TWO-PERIOD, CROSSOVER DEPIST-COVID TRIAL" for consideration by PLOS Medicine. Your manuscript has now been evaluated by the PLOS Medicine editorial staff and I am writing to let you know that we would like to send your submission out for external assessment. However, we first need you to complete your submission by providing the metadata that are required for full assessment. To this end, please login to Editorial Manager where you will find the paper in the 'Submissions Needing Revisions' folder on your homepage. Please click 'Revise Submission' from the Action Links and complete all additional questions in the submission questionnaire. Please re-submit your manuscript within two working days, i.e. by Jun 08 2023 11:59PM. Login to Editorial Manager here: https://www.editorialmanager.com/pmedicine Once your full submission is complete, your paper will undergo a series of checks in preparation for external assessment. Feel free to email us at plosmedicine@plos.org if you have any queries relating to your submission. Kind regards, Richard Turner PhD Consulting Editor, PLOS Medicine plosmedicine@plos.org 17 Aug 2023 Dear Dr. Leblanc, Thank you very much for submitting your manuscript "INTENSIFIED SCREENING FOR SARS-CoV-2 IN 18 EMERGENCY DEPARTMENTS THE CLUSTER-RANDOMIZED, TWO-PERIOD, CROSSOVER DEPIST-COVID TRIAL" (PMEDICINE-D-23-01467R1) for consideration at PLOS Medicine. Your paper was evaluated by an associate editor and discussed among all the editors here. It was also discussed with an academic editor with relevant expertise, and sent to independent reviewers, including a statistical reviewer. The reviews are appended at the bottom of this email and any accompanying reviewer attachments can be seen via the link below: [LINK] In light of these reviews, I am afraid that we will not be able to accept the manuscript for publication in the journal in its current form, but we would like to consider a revised version that addresses the reviewers' and editors' comments. Obviously we cannot make any decision about publication until we have seen the revised manuscript and your response, and we plan to seek re-review by one or more of the reviewers. In revising the manuscript for further consideration, your revisions should address the specific points made by each reviewer and the editors. Please also check the guidelines for revised papers at http://journals.plos.org/plosmedicine/s/revising-your-manuscript for any that apply to your paper. In your rebuttal letter you should indicate your response to the reviewers' and editors' comments, the changes you have made in the manuscript, and include either an excerpt of the revised text or the location (eg: page and line number) where each change can be found. Please submit a clean version of the paper as the main article file; a version with changes marked should be uploaded as a marked up manuscript. In addition, we request that you upload any figures associated with your paper as individual TIF or EPS files with 300dpi resolution at resubmission; please read our figure guidelines for more information on our requirements: http://journals.plos.org/plosmedicine/s/figures. While revising your submission, please upload your figure files to the PACE digital diagnostic tool, https://pacev2.apexcovantage.com/. PACE helps ensure that figures meet PLOS requirements. To use PACE, you must first register as a user. Then, login and navigate to the UPLOAD tab, where you will find detailed instructions on how to use the tool. If you encounter any issues or have any questions when using PACE, please email us at PLOSMedicine@plos.org. We expect to receive your revised manuscript by Sep 06 2023 11:59PM. Please email us (plosmedicine@plos.org) if you have any questions or concerns. ***Please note while forming your response, if your article is accepted, you may have the opportunity to make the peer review history publicly available. The record will include editor decision letters (with reviews) and your responses to reviewer comments. If eligible, we will contact you to opt in or out.*** We ask every co-author listed on the manuscript to fill in a contributing author statement, making sure to declare all competing interests. If any of the co-authors have not filled in the statement, we will remind them to do so when the paper is revised. If all statements are not completed in a timely fashion this could hold up the re-review process. If new competing interests are declared later in the revision process, this may also hold up the submission. Should there be a problem getting one of your co-authors to fill in a statement we will be in contact. YOU MUST NOT ADD OR REMOVE AUTHORS UNLESS YOU HAVE ALERTED THE EDITOR HANDLING THE MANUSCRIPT TO THE CHANGE AND THEY SPECIFICALLY HAVE AGREED TO IT. You can see our competing interests policy here: http://journals.plos.org/plosmedicine/s/competing-interests. Please use the following link to submit the revised manuscript: https://www.editorialmanager.com/pmedicine/ Your article can be found in the "Submissions Needing Revision" folder. To enhance the reproducibility of your results, we recommend that you deposit your laboratory protocols in protocols.io, where a protocol can be assigned its own identifier (DOI) such that it can be cited independently in the future. Additionally, PLOS ONE offers an option to publish peer-reviewed clinical study protocols. Read more information on sharing protocols at https://plos.org/protocols?utm_medium=editorial-email&utm_source=authorletters&utm_campaign=protocols Please ensure that the paper adheres to the PLOS Data Availability Policy (see http://journals.plos.org/plosmedicine/s/data-availability), which requires that all data underlying the study's findings be provided in a repository or as Supporting Information. For data residing with a third party, authors are required to provide instructions with contact information for obtaining the data. PLOS journals do not allow statements supported by "data not shown" or "unpublished results." For such statements, authors must provide supporting data or cite public sources that include it. We look forward to receiving your revised manuscript. Sincerely, Alexandra Schaefer, PhD PLOS Medicine plosmedicine.org ----------------------------------------------------------- Requests from the editors: GENERAL COMMENTS Please respond to all editor and reviewer comments. Please cite the reference numbers in square brackets (e.g., “We used the techniques developed by our colleagues [19] to analyze the data”). Citations should be preceding punctuation. Please cite your Supporting Information as outlined here: https://journals.plos.org/plosmedicine/s/supporting-information Causal language - In trials, there is usually a distinction in the language in terms of causal vs associational for primary and secondary trial outcomes. It would be beneficial to use associational language in the discussion and other sections for secondary outcomes. ACADEMIC EDITOR COMMENTS - I agree with one of the reviewers who said that there should be more information on the screening of the community in Paris. How was this data collected and how representative is the screened population? - It was at some points unclear whether authors were referring to the data from community screening or to results from modelling. Maybe clarify upfront that these two sources are used for comparison with the general population and clarify throughout the manuscript which of two you are referring to. - In the tables, the term "control strategy" for denoting data collected during control periods could potentially be misleading. In my understanding, the term "control strategy" refers to a strategy to control the pandemic, and not control in the sense of control group. I suggest to write "control periods" and "intervention periods" or something similar. COMPETING INTEREST STATEMENT All authors must declare their relevant competing interests per the PLOS policy, which can be seen here: https://journals.plos.org/plosmedicine/s/competing-interests For authors with ties to industry, please indicate whether any of the interests has a financial stake in the results of the current study. FINANCIAL DISCLOSURE The funding statement should include: specific grant numbers, initials of authors who received each award, URLs to sponsors’ websites. Also, please state whether any sponsors or funders (other than the named authors) played any role in study design, data collection and analysis, the decision to publish, or preparation of the manuscript. If they had no role in the research, include this sentence: “The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.” DATA AVAILABILITY STATEMENT PLOS Medicine requires that the de-identified data underlying the specific results in a published article be made available, without restrictions on access, in a public repository or as Supporting Information at the time of article publication, provided it is legal and ethical to do so. Please see the policy at http://journals.plos.org/plosmedicine/s/data-availability and FAQs at http://journals.plos.org/plosmedicine/s/data-availability#loc-faqs-for-data-policy The Data Availability Statement (DAS) requires revision. For each data source used in your study: a) If the data are freely or publicly available, note this and state the location of the data: within the paper, in Supporting Information files, or in a public repository (include the DOI or accession number). b) If the data are owned by a third party but freely available upon request, please note this and state the owner of the data set and contact information for data requests (web or email address). Note that a study author cannot be the contact person for the data. c) If the data are not freely available, please describe briefly the ethical, legal, or contractual restriction that prevents you from sharing it. Please also include an appropriate contact (web or email address) for inquiries (again, this cannot be a study author). In accordance with ICMJE requirements, PLOS Medicine requires prospective, public registration of a data sharing plan (as part of mandatory clinical trials registration) for all clinical trials that began enrollment on or after January 1, 2019. ABSTRACT Please report your abstract according to CONSORT for abstracts, following the PLOS Medicine abstract structure (Background, Methods and Findings, Conclusions); https://www.equator-network.org/reporting-guidelines/consort-abstracts/ Please ensure that all numbers presented in the abstract are present and identical to numbers presented in the main manuscript text. PLOS Medicine requests that main results are quantified with 95% CIs as well as p values. Please include. When reporting p values please report as p<0.001 and where higher as the exact p value p=0.002, for example. For the purposes of transparent data reporting, if not including the aforementioned please clearly state the reasons why not. Please include any important dependent variables that are adjusted for in the analyses. Throughout, suggest reporting statistical information as follows to improve clarity for the reader “22% (95% CI [13%,28%]; p38°) or feeling Feverish’, please add a unit (Celsius). eSupplement S6: Please define ‘ED’ or change to ‘Emergency department’. eSupplement S7: Please define ‘y.o.’. eSupplement S8: Please define ‘med’, ‘Q’, ‘CI’. eSupplement S9/eTable 1: Please define ‘CI’. eSupplement S9/eTable 2: Please define ‘SE’. eSupplement S9/eTable 3/5/6: Please define ‘SE’, ‘CI’. eSupplement S9/eTable 4: Please define ‘ED’, ‘SE’, ‘CI’. eSupplement S10: Please define ‘ED’, ‘CI’. eSupplement S11: Please define ‘ED’. Please increase the size of the figure legend and the axis label. Please revise throughout the entire manuscript. REFERENCES PLOS uses the numbered citation (citation-sequence) method and first six authors, et al. Please ensure that journal name abbreviations match those found in the National Center for Biotechnology Information (NCBI) databases (http://www.ncbi.nlm.nih.gov/nlmcatalog/journals), and are appropriately formatted and capitalised. Please also see https://journals.plos.org/plosmedicine/s/submission-guidelines#loc-references for further details on reference formatting. Where website addresses are cited, please specify the date of access. Comments from the reviewers: Reviewer #1: The Authors present an very interesting manuscript about the value of screening for asymptomatic or paucisymptomatic patients in addition to routine screening for the detection of SARSCoV-2 infection in the emergency departments (EDs). The intensified screening strategy took place in the year 2021 in EDs of the Paris metropolitan area, in addition to routine screening practice. The intensified screening strategy consisted of a questionnaire about risk exposure and symptoms offered by nurses to asymptomatic/paucisymptomatic patients from February 17, 2021, to May 31, 2021. The primary outcome was the proportion of newly diagnosed SARS-CoV-2-positive patients among all adults visiting EDs. During the intervention period, 17,512 patients were screened in routine practice, resulting in 1,635 (9.3%) new SARS-CoV-2 diagnoses while 4,283 patients were screened with the intensified screening strategy , resulting in 224 new diagnoses (5.2%). In total, 1,859 patients were newly diagnosed among 69,248 ED admitted patients. The Authors conclusion is that an intensified ED screening strategy is unlikely to identify a substantial proportion of new diagnoses if the intensified screening is aimed at asymptomatic patietns who are unlikely to refer to ED. This data is functional to the concern that adding SARS CoV-2 screening in ED will have unintended consequences for ED workload, work capacity and length of stay. I would ask the Authours a brief comment in the discussion on the cost of using the ID NOW molecular platform in ED setting in their designed strategy of intensifying SARS CoV-2 testing. Reviewer #2: This manuscript by Leblanc et al. evaluates an expanded and targeted SARS-CoV-2 screening strategy intervention in 18 EDs in the Paris region using a cluster-randomized, two-period, crossover trial serendipitously performed over a major peak of regional SARS-CoV-2 transmission between February and June of 2021. The authors demonstrate that their expanded screening strategy did not identify a significantly higher proportion of new cases compared to the control screening methodology during this dynamic interval of rapidly changing disease prevalence. The trial was expertly performed, the analyses are thorough and robust, and the manuscript is well-written. I offer the following suggestions to improve the breadth of interpretations in the discussion. 1) In response to a previous round of reviews, the authors have appropriately tempered initial claims of systematic screening and used the terminology "intensified screening." The authors' study seems most consistent with a "targeted" screening strategy as it relies upon nurse-directed implementation of a questionnaire prior to selecting an appropriate screening test for the disease of interest. As others have previously shown in a low prevalence disease setting (doi: 10.1001/jamanetworkopen.2021.17763), targeted screening strategies do not typically increase the number of new diagnoses when the prevalence of disease is low but do reduce the number of tests administered to the population of interest. The present study was performed during a period of very high disease prevalence and an untargeted study design (free testing offered to anyone without the implementation of an initial questionnaire) may have achieved much higher than 13.6% participation in the screening process which may have corresponded to more cases diagnosed. While previously published data evaluating low-prevalence disease settings do not suggest that this would have changed the authors results or conclusions, it is important to note in the discussion that the 13.6% participation rate was potentially lower than it otherwise might have been due to the targeted nature of the screening process. It is also unclear in the setting of a very high prevalence disease setting if increased participation rates might have changed the results in favor of universal screening - emphasizing the importance of being very clear that the present study evaluated a targeted screening strategy rather than an untargeted strategy. Clearly, the authors had no way to know during study planning that the study interval would be perfectly timed to coincide with the peak of a major outbreak of disease, therefore their design of a targeted screening strategy was completely justified, and this is not a major study limitation - just one that should be made as transparent as possible in the discussion. The authors should address in the discussion their results that further support that their screening methodology was ultimately targeted - especially the fact that the factor most strongly associated with performing screening for asymptomatic/paucisymptomatic patients was the presence of mild symptoms (OR 2.1-3.7, line 290). The higher frequency of disease found in the 4,283 screening tests offered during the intervention period when compared with the 3.4 million screening tests performed in the Paris Metropolitan region in the same time interval also strongly suggests that there was some selection bias in who received the testing. Whether this was a location-specific bias because all these patients were seen in an acute care medical setting or if this was related to the selection bias of the specific patients who chose to take / were offered the questionnaire cannot be deduced from the present data. Nevertheless, being clear in the discussion that these results together with the study design suggest that the screened population was targeted will allow the practicing ED clinician to realize that the present results are only generalizable to a targeted screening strategy implemented during a high-prevalence interval during a pandemic/epidemic wave rather than to an untargeted screening strategy implemented at those same times or to a targeted screening strategy implemented at a time of low disease prevalence. 2) While not a limitation of the authors present study, the authors should consider adding a paragraph to the discussion of the consequences of implementing a test such as the rapid isothermal amplification assay with a specificity of > 97.5% during a period of low disease prevalence. They appropriately address this last comment from the previous reviewer #1 by stating that it is not an issue in their study where there was such high prevalence of disease. However, those who are contemplating expanding asymptomatic screening during periods of low disease prevalence, as that reviewer appeared to be advocating, will need to consider tests with only the highest specificity or the proportion of false positive results can rapidly diminish the utility of any screening strategy. The authors should comment how any future considerations of expanded screening for viral respiratory diseases should consider both the prevalence of disease and the specificity and sensitivity of individual tests in addition to cost-effectiveness. This has become acutely apparent in the past several months as some hospital systems continue to insist upon universal SARS-CoV-2 screening strategies for admitted patients when the prevalence of disease has diminished substantially. Reviewer #3: Statistical review This paper reports a cluster-crossover trial evaluating a screening strategy in emergency departments for covid. It is shown that this doesn't significantly change the number of infections identified. The trial is analysed with appropriate methods and is reported very well. I have some minor comments: 1. Abstract: In the findings paragraph it would be useful to add more about the number screened in the Paris metropolitan region. 2. Methods: I also found information lacking about the screening in Paris metropolitan region - was this routinely collected data or conducted as part of the research study? It's possible this estimate was treated as a known, fixed value in which case I would recommend this is made clearer in the paper. 3. Statistical analysis: where 'patient characteristics' are referred to, I would recommend these are provided somewhere. 4. Page 7: "estimated using the KR or containment method." - what affected which method was used? 5. Page 8: The "Miettinen-Nurminen (MN)" method was new to me, can more be said about what this does and justifying its use? Is this because the data available was a 2x2 table? 6. Page 8: "calculated by profile (diagnoses through screening for asymptomatic…". I would recommend clarifying this sentence: "The proportion was calculated separately for different profiles of patients. These profiles included 'diagnoses through screening for asymptomatic/paucisymptomatic patients' and 'all cases'." If something else is meant by calculated by profile, I would make this clearer. 7. Page 11: I think 'IC on line 300' should be CI. James Wason Any attachments provided with reviews can be seen via the following link: [LINK] 6 Sep 2023 Submitted filename: Response_Editor_reviewers_R1_20230906.docx Click here for additional data file. 18 Oct 2023 Dear Dr. Leblanc, Thank you very much for re-submitting your manuscript "INTENSIFIED SCREENING FOR SARS-CoV-2 IN 18 EMERGENCY DEPARTMENTS THE CLUSTER-RANDOMIZED, TWO-PERIOD, CROSSOVER DEPIST-COVID TRIAL" (PMEDICINE-D-23-01467R2) for review by PLOS Medicine. I would like to thank you for your considered and detailed responses to the editors' and reviewers' comments. I have discussed the paper with my colleagues and the academic editor, and it has also been seen again by two of the original reviewers. The changes made to the paper were satisfactory to the reviewers, and any remaining comments are editorial in nature. As such, we intend to publish the paper in PLOS Medicine. However, before we can officially accept the paper, we kindly request that you address a few additional editorial comments (found below). When submitting your revised paper, please include once again a detailed point-by-point response to the editorial comments. The remaining issues that need to be addressed are listed at the end of this email. Any accompanying reviewer attachments can be seen via the link below. Please take these into account before resubmitting your manuscript: [LINK] ***Please note while forming your response, if your article is accepted, you may have the opportunity to make the peer review history publicly available. The record will include editor decision letters (with reviews) and your responses to reviewer comments. If eligible, we will contact you to opt in or out.*** In revising the manuscript for further consideration here, please ensure you address the specific points made by each reviewer and the editors. In your rebuttal letter you should indicate your response to the reviewers' and editors' comments and the changes you have made in the manuscript. Please submit a clean version of the paper as the main article file. A version with changes marked must also be uploaded as a marked up manuscript file. Please also check the guidelines for revised papers at http://journals.plos.org/plosmedicine/s/revising-your-manuscript for any that apply to your paper. If you haven't already, we ask that you provide a short, non-technical Author Summary of your research to make findings accessible to a wide audience that includes both scientists and non-scientists. The Author Summary should immediately follow the Abstract in your revised manuscript. This text is subject to editorial change and should be distinct from the scientific abstract. We expect to receive your revised manuscript within 1 week. Please email me (aschaefer@plos.org) if you have any questions or concerns. We ask every co-author listed on the manuscript to fill in a contributing author statement. If any of the co-authors have not filled in the statement, we will remind them to do so when the paper is revised. If all statements are not completed in a timely fashion this could hold up the re-review process. Should there be a problem getting one of your co-authors to fill in a statement we will be in contact. YOU MUST NOT ADD OR REMOVE AUTHORS UNLESS YOU HAVE ALERTED THE EDITOR HANDLING THE MANUSCRIPT TO THE CHANGE AND THEY SPECIFICALLY HAVE AGREED TO IT. Please ensure that the paper adheres to the PLOS Data Availability Policy (see http://journals.plos.org/plosmedicine/s/data-availability), which requires that all data underlying the study's findings be provided in a repository or as Supporting Information. For data residing with a third party, authors are required to provide instructions with contact information for obtaining the data. PLOS journals do not allow statements supported by "data not shown" or "unpublished results." For such statements, authors must provide supporting data or cite public sources that include it. To enhance the reproducibility of your results, we recommend that you deposit your laboratory protocols in protocols.io, where a protocol can be assigned its own identifier (DOI) such that it can be cited independently in the future. Additionally, PLOS ONE offers an option to publish peer-reviewed clinical study protocols. Read more information on sharing protocols at https://plos.org/protocols?utm_medium=editorial-email&utm_source=authorletters&utm_campaign=protocols Please review your reference list to ensure that it is complete and correct. If you have cited papers that have been retracted, please include the rationale for doing so in the manuscript text, or remove these references and replace them with relevant current references. Any changes to the reference list should be mentioned in the rebuttal letter that accompanies your revised manuscript. Please note, when your manuscript is accepted, an uncorrected proof of your manuscript will be published online ahead of the final version, unless you've already opted out via the online submission form. If, for any reason, you do not want an earlier version of your manuscript published online or are unsure if you have already indicated as such, please let the journal staff know immediately at plosmedicine@plos.org. If you have any questions in the meantime, please contact me (aschaefer@plos.org) or the journal staff on plosmedicine@plos.org. We look forward to receiving the revised manuscript by Oct 25 2023 11:59PM. Sincerely, Alexandra Schaefer, PhD Associate Editor PLOS Medicine plosmedicine.org ------------------------------------------------------------ Requests from Editors: TITLE 1) We suggest changing the title to: “Intensified screening for SARS-CoV-2 in emergency departments in Paris, France (DEPIST-COVID): A cluster-randomized, two-period, crossover trial” FINANCIAL DISCLOSURE 1) If possible, please include specific grant numbers in your funding statement. DATA AVAILABILITY STATEMENT 1) Thank you for updating your Data availability statement. We suggest changing the statement as follows: “The study data are owned by the Assistance Publique - Hôpitaux de Paris (AP-HP) sponsor, “Département de la Recherche Clinique et du Développement” and are not freely available. Requests to access the data should be directed to: DJENNAOUI Fatiha and [DRC] Secretariat Promotion Délégation à la Recherche Clinique et à l'Innovation .” ABSTRACT 1) We noted that you provided the CONSORT Abstract checklist as a supplementary file. You do not need to provide the actual file, but we would like to encourage you to revise your abstract once more following the CONSORT Abstract checklist. We have pointed out some specific items in the following points. 2) Please only report the primary outcome of the trial in your abstract. We are in the process of overhauling our workflows and policies (with a new Executive Editor), and we now require that trial abstracts only report secondary outcomes if all secondary outcomes of the trial are included. For trials that have many secondary outcomes, such as yours, the abstract should be limited to reporting the primary outcome. 3) At the beginning of the Methods/Findings section of the abstract, please change ‘During this cluster-randomized…’ to ‘We conducted a cluster-randomized…’. 4) Please include the clinical trial registry number in the abstract. 5) In the last sentence of the Abstract Methods and Findings section, please describe the main limitation(s) of the study's methodology (e.g., “The main limitation of the study is that it was conducted in a rapidly evolving epidemiologic context.”) 6) “The ED population seems to be more affected than the population of the region” – this statement and the conclusion paragraph seem rather unclear. Please revise the conclusion paragraph for clarity and aim to focus on the study implications and the interpretation of the study based on the primary results presented in the abstract. AUTHOR SUMMARY 1) The Author Summary requires revision. Under the second question ‘What Did the Researchers Do and Find?, the bullet points, particularly the second one, are rather long and we encourage you to focus on the most important outcome (i.e. the primary outcome). To improve clarity, we also suggest changing the bullet points under ‘Why Was This Study Done?’ as follows: • Undetected asymptomatic SARS-CoV-2 infections or paucisymptomatic infections with mild symptoms are responsible for a substantial portion of transmissions, which has been a major challenge for managing the COVID-19 pandemic. • Free and widely available screening has been offered in many countries to reach asymptomatic or paucisymptomatic infectious individuals and improve detection, reduce transmission, and help contain the pandemic. • The value of systematically offering screening during medical consultations, particularly in emergency departments (EDs), as a possible strategy to identify asymptomatic/paucisymptomatic infectious individuals has, to our knowledge, not been evaluated. 2) The last bullet under ‘What Do These Findings Mean?’ point should describe the main limitation of the study's methodology. INTRODUCTION 1) ll.119-120, suggest: A recent systematic review also pointed out these studies were modeling studies or retrospective observational analyses not conducted in a controlled environment [9]. 2) l.137: Please add the time point for the “vaccine roll-out”. METHODS AND RESULTS 1) ll.317-320: There seems to be a formatting issue – please revise. FIGURES 1) Figure 3: Please include in the figure description an explanation of the meaning of the black line. CHECKLIST 1) Thank you for providing your Consort 2010 statement: extension to cluster randomised trials checklist. Please replace the page numbers with paragraph numbers per section (e.g. "Methods, paragraph 1"), since the page numbers of the final published paper may be different from the page numbers in the current manuscript. SUPPLEMENT 1) eSupplement S9/eTable 6: Please remove the ‘E’ from ‘Standard Error E’. 2) eSupplement S11 Figure 1: I assume that the dots/lines for "lockdown 2021" are not meant to show values, but to represent the time period of the lockdown. I would suggest using a shaded area in the background instead of the dots/line to mark this time period so that it is not confused with the actual values displayed with the other dots and lines for 2019 and 2021. 3) In Figures eSupplement S11 Figure 1 and Figure 2, please show the axis beginning at zero. If this is not possible, please show a break in the axis. SOCIAL MEDIA To help us extend the reach of your research, please provide any X (formerly known as Twitter) handle(s) that would be appropriate to tag, including your own, your coauthors’, your institution, funder, or lab. Please respond to this email with any handles you wish to be included when we tweet this paper. Comments from Reviewers: Reviewer #2: I am in agreement that there is no clear definition of targeted screening (DOI: 10.1016/j.lanepe.2022.100353). The design of the study with a questionnaire asking about risk factors for illness and symptoms prior to testing at the very least served as a potential barrier to broader uptake of universal screening in these EDs than simply verbally offering a test to everyone during triage. In addition, the data presented by the authors suggests that the whole process led to enrichment of individuals who had mild symptoms in the screened population. How to define what those limitations are is irrelevant, as long as they are acknowledged and they are in the submitted manuscript. The authors have addressed many issues raised for this re-submission and I have no further concerns. Reviewer #3: Thank you to the authors for addressing my previous comments well. I have no further issues to raise. Any attachments provided with reviews can be seen via the following link: [LINK] 25 Oct 2023 Submitted filename: Response_Editor_R2_20231025.docx Click here for additional data file. 2 Nov 2023 Dear Dr Leblanc, On behalf of my colleagues, I am pleased to inform you that we have agreed to publish your manuscript "INTENSIFIED SCREENING FOR SARS-CoV-2 IN 18 EMERGENCY DEPARTMENTS IN THE PARIS METROPOLITAN AREA, FRANCE (DEPIST-COVID): A CLUSTER-RANDOMIZED, TWO-PERIOD, CROSSOVER TRIAL" (PMEDICINE-D-23-01467R3) in PLOS Medicine. Prior to final acceptance, please make the following changes: In the data statement (submission form) please briefly state the reason the data are not publicly available, e.g., for protection of participant confidentiality; At line 25 (abstract), please remove "18"; In the abstract, around line 32, please add a sentence to describe the randomization process, e.g., "At the start of the first period, 18 EDs were randomized to the intervention or control strategy by balanced block randomization with stratification, with the alternative condition being applied in the second period."; At line 38, we suggest "... by intention-to-treat"; At line 52, and in other places in the text where similar wording occurs, we suggest adapting the text to "In this study, we found that intensified screening ..."; In the author summary, please use the active voice in one or two places, e.g., at line 69 "We identified whether an intensified ..."; At line 402 (Discussion section), we suggest adapting the text to "... who would not otherwise have been screened ...". Before your manuscript can be formally accepted you will need to complete some formatting changes, which you will receive in a follow up email. Please be aware that it may take several days for you to receive this email; during this time no action is required by you. Once you have received these formatting requests, please note that your manuscript will not be scheduled for publication until you have made the required changes. In the meantime, please log into Editorial Manager at http://www.editorialmanager.com/pmedicine/, click the "Update My Information" link at the top of the page, and update your user information to ensure an efficient production process. PRESS We frequently collaborate with press offices. If your institution or institutions have a press office, please notify them about your upcoming paper at this point, to enable them to help maximise its impact. If the press office is planning to promote your findings, we would be grateful if they could coordinate with medicinepress@plos.org. If you have not yet opted out of the early version process, we ask that you notify us immediately of any press plans so that we may do so on your behalf. We also ask that you take this opportunity to read our Embargo Policy regarding the discussion, promotion and media coverage of work that is yet to be published by PLOS. As your manuscript is not yet published, it is bound by the conditions of our Embargo Policy. Please be aware that this policy is in place both to ensure that any press coverage of your article is fully substantiated and to provide a direct link between such coverage and the published work. For full details of our Embargo Policy, please visit http://www.plos.org/about/media-inquiries/embargo-policy/. To enhance the reproducibility of your results, we recommend that you deposit your laboratory protocols in protocols.io, where a protocol can be assigned its own identifier (DOI) such that it can be cited independently in the future. Additionally, PLOS ONE offers an option to publish peer-reviewed clinical study protocols. Read more information on sharing protocols at https://plos.org/protocols?utm_medium=editorial-email&utm_source=authorletters&utm_campaign=protocols Thank you again for submitting to PLOS Medicine. We look forward to publishing your paper. Sincerely, Richard Turner PhD, for Alexandra Schaefer, PhD Consulting editor, PLOS Medicine plosmedicine@plos.org